Searched for
TARO EARNINGS
Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growthSun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and Indi...
- Sun Pharma Q1 preview: Weak Taro show, soft US sales to weigh on earningsConsolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is sc...
- Sun Pharma’s selloff gives a fright to its rivals tooThe Nifty Pharma index tumbled 3% with Sun shares dropping 4.3% to a sixmonth low.
- What class action suit against Taro means for Sun PharmaAnalysts were jittered by the DOJ investigation of drug pricing, with some brokerages cutting down the forecast for the Indian pharma secto...
- Taro appoints Mariano Balaguer its new CFOTaro said Balaguer comes with 20 years of experience in finance with global companies such a Novartis Consumer Health, Nestle and Henry Sch...
- Sun Pharma falls despite earnings being in line with estimatesProfit were in line with estimates despite hopes of a better show after unit Taro Pharmaceutical Industries reported higher earnings earlie...
- Expect Sun Pharma's earnings growth to be above 20% in two years: Prashasta Seth"The kind of margins that you are getting in Taro are simply incredible," Seth said.
- Sun Pharma gains on Taro earnings, US FDA nod to sell generic DoxilShares of Sun Pharmaceutical Industries were in action in early trade after its Israel-based subsidiary reported better-than-expected resul...
- Sun Pharma says won't revise taro offer priceMumbai-based Sun Pharma will not revise its offer price to minority shareholders of Isreali drug maker Taro pharma, a company official said.
- Taro Pharmaceuticals' excellent Q4 performance may kill Sun Pharma buyoutSun Pharma's proposed buyout of Taro Pharmaceuticals might have been "killed" by the Israeli company's exceptional Q4 performance, said med...
- Sun Pharma: Product pipeline to help maintain tempoThough y-o-y comparison in case of its overseas business has been rendered unviable, the company has showed improved performance in this bu...
- Taro contributed one third of Sun Pharma's consolidated net salesBarring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product range in the US fell below the expe...
- Taro contributed one third of Sun Pharma's consolidated net salesBarring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product range in the US fell below the expe...
- Pharma major, Sun, back on growth trackAfter facing a regulatory clampdown by the US FDA in 2009, Caraco has had its manufacturing suspended. It now sells distributed products.
- Taro to shut down Irish plant to control lossesIsraeli drugmaker Taro Pharma on Thursday said it is closing its Irish manufacturing plant to stem further losses, inviting allegations of ...
- BNP Paribas maintains 'buy' Sun PharmaBNP Paribas has maintained its ‘buy’ rating on Sun Pharma and also its price target of Rs 1,695 after the company initiated an out-of-court...
- Taro bid: Sun sees long battle aheadSun Pharma's proposed takeover of Taro Pharmaceuticals could be a drawn-out affair, a company official said.
- Sun Pharma's found its shine in Taro acquisitionSun Pharmaceuticals’ acquisition of Taro Pharma ends its long wait to find a suitable target.
Load More
